ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements
Acutaas Chemicals Limited has announced the re-appointment of Ram Mohan Lokhande as Executive Director and Anita Bandyopadhyay as Non-Executive Independent Director for a 60-month term.
Acutaas Chemicals will acquire 100% of Enchem Ami Organics Private Limited for Rs. 1 Lakh, making it a wholly owned subsidiary.
Acutaas Chemicals will acquire 100% equity stake in step-down subsidiary Enchem Ami Organics for Rs. 1 Lakh, making it a direct wholly-owned subsidiary.
Acutaas Chemicals Limited conducted its 19th Annual General Meeting on September 24, 2026, where shareholders transacted various ordinary and special business items.
Acutaas Chemicals Limited has received a patent from the Indian Patent Office for a process to prepare 2,4-dimethylthiophenol. The company now holds 11 patents.
Acutaas Chemicals Limited inaugurated a new state-of-the-art Pilot Plant at Unit 1 in Sachin, Surat. The facility supports R&D for high potency active pharmaceutical ingredients.
Acutaas Chemicals Limited has set September 17, 2026, as the record date for its final dividend of Rs. 2.50 per share for FY 2025-26.
Acutaas Chemicals Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26. This filing complies with the SEBI LODR regulations.
Acutaas Chemicals Limited has submitted its Annual Report for the financial year 2025-26. The document contains comprehensive performance details, strategic updates, and statutory reports.
Acutaas Chemicals Limited has issued a notice for its 19th Annual General Meeting on September 24, 2026, to consider financial statements, director appointments, and related-party transaction limits.
Acutaas Chemicals' subsidiary, Indichem Inc., inaugurated its semiconductor materials manufacturing plant in South Korea. The new facility enhances the company's semiconductor supply chain capabilities.
Acutaas Chemicals approved a Rs. 212 Crore capital expenditure plan for a new manufacturing plant in Gujarat. The Board also announced the upcoming 19th AGM.
Acutaas Chemicals received approval for incentives under the Electronics Components Manufacturing Scheme. The company expects benefits of 25% on an eligible investment of ₹119.12 Crore.
Acutaas Chemicals Limited received MeitY approval for an incentive package under the Electronics Components Manufacturing Scheme. The company is expected to receive incentives up to 25% of Rs.119.12 Crore.
Acutaas Chemicals delivered a robust Q1 FY27 with 59.1% revenue growth, fueled by strong CDMO and Advanced Pharmaceutical Intermediates (API) performance.
Acutaas Chemicals delivered strong Q1 FY27 results with 59% YoY revenue growth. Management is focused on scaling high-margin Pharma Intermediates and CDMO segments while maintaining operational efficiencies.
Acutaas Chemicals reported Q1 FY27 revenue of ₹329.7 crore and PAT of ₹75 crore. Revenue grew 59.1% YoY with PAT margins at 22.7%.
Acutaas Chemicals Ltd reported revenue from operations of ₹329.7 Cr (+59.1% YoY) and net profit of ₹75 Cr (+70.5% YoY) for Q1 FY27.
Acutaas Chemicals approved its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The board meeting concluded on July 24, 2026.
Acutaas Chemicals scheduled a board meeting for July 24, 2026. The board will consider the unaudited financial results for the June 30, 2026 quarter.
Acutaas Chemicals promoted Mr. Anurag Shukla to General Manager Operations & Unit Head. The designation as SMP took effect July 2, 2026.
Acutaas Chemicals Limited's subsidiary ACEPL issued shares to A.R.Z Pharma Ltd for ₹5.83 Crore. Consequently, the parent's stake in ACEPL reduced from 100% to 90%.
Acutaas Chemicals Ltd subsidiary ACEPL allotted shares worth ₹5.83 Crore to A.R.Z Pharma Ltd. Consequently, ACEPL ceased being wholly-owned, with the parent's stake diluting to 90%.
Acutaas Chemicals Limited announced the resignation of Senior General Manager Trilok Vasant Sontakke. His departure, effective May 15, 2026, is cited due to personal reasons.
Acutaas Chemicals delivered record FY26 results with Revenue of ₹13,394 Mn and PAT of ₹3,564 Mn, driven by expansion in pharmaceutical and semiconductor segments.
Acutaas Chemicals delivered record FY26 performance with ₹1,339.4cr revenue and ₹356.4cr PAT, driven by strong CDMO business and portfolio reshuffling towards high-value pharmaceutical intermediates.
Acutaas Chemicals Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by M/s Kashyap Shah & Co., confirms the company's adherence to SEBI regulations and statutory provisions. No material non-compliances or observations were noted for the review period.
Acutaas Chemicals delivered strong performance in Q4 FY26, with revenue up 40% and PAT doubling, driven by the high-margin CDMO business and specialty chemicals recovery despite supply chain disruptions.
Acutaas Chemicals Limited has recommended a final dividend of ₹0.5 per equity share for the financial year 2025-26. The dividend is subject to shareholder approval at the upcoming General Meeting. The record date and meeting date will be announced in due course.
Acutaas Chemicals Limited confirmed it is not classified as a Large Corporate for FY 2026-27 under SEBI norms. The company reported outstanding borrowings of ₹24.05 Crore as of March 31, 2026, and maintains a CARE A1+ credit rating.